Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II thalidomide dose-ranging study in active ankylosing spondylitis
ChiCTR-TRC-13003449Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of thalidomide in ankylosing spondylitis (AS) (3 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Proportion of subjects achieving ASAS20 at week 12. Started Feb 2013; status: completed.
02
Drugs
thalidomide
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR-TRC-13003449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003449.